Recent studies indicated that the transdifferentiation of adenocarcinoma cells into treatment-emergent NEPC (t-NEPC) is a critical mechanism of drug resistance after treatment with the second generation AR antagonists [17], and NEPC cells share the common characteristics of PCSCs [44]. The gene discussed is AR; the disease is adenocarcinoma.